Replies to post #124789 on OWC Pharmaceutical Research Corp (OWCP)

[moxa1]

IMO it's because we don't have a product on the market. Simple as that. I think we'll see a big spike once the safety study is complete. That's the only hurdle remaining before someone brings CanaPsor to market.

[Farmer7]

Product/revenue could be a driver of it. If there's institutional investors in them can also make a difference as owcp has very few institutional investors. I own a fair amount of Gwph and CNBX also, but own the biggest share of OWCP. I own it that way because I've always thought we are deeply undervalued compared to these other companies. I think this will all change after Q1.

[Specialneeds]

I bought into this company last spring due to an anticipation that the creme would hit the market in 2017 which could fund further research. Many investors like may have felt that we were given an impression from OWC that this was the case but not really based in facts. I think this has something to do with our price lagging others. This may very well been caused by Ziv. I strongly believe that Hirsch would not have agreed to the chairman position unless the products in the pipeline have very strong potential. I think that he is making sure that there are no more head fakes on product distribution. Once we establish that product distribution is going to take place tomorrow n the he near future the market cap goes to 200 to 250 m very quickly.

[Farmer7]

I should bring one last thing to your attention regarding share structure of these two companies we are comparing. Owcp has roughly 27 million more OS shares then CNBX. But the big difference is in the float, where Owcp has close to 90 million and CNBX has 30 million.... ironically a third, and as you said we are trading at a third of there price. So when people come to buy, that one in theory will move faster upwards then OWCP. Again though, at the end of the day its products that will make the longterm difference, and we have just that coming for 2018 and beyond.